Drug Trial Radar · NCT07672561
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
375
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Nov 30, 2026
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Zhejiang Wenda Pharma Technology LTD.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
Drug:WD-890Drug
WD-890 tablet will be administered orally.
Drug: placeboDrug
Placebo tablet will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) at Weeks 16Time frame: Screening up to Week 16
- Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16Time frame: Screening up to Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital of Dermatology, Chinese Academy of Medical Sciences
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.